1994PubMedRequires access

[Second generation non-sedative antihistaminics].

N Bakos

Open publisher page 0 citations

Abstract

In the 1980's a new group of antihistamines was developed, which has got, besides its increased efficiency, fewer by effects. Considering their pharmacokinetic characteristics and effects, the requirements the modern second generation antihistamine should meet, can be summarized as follows: the modern antihistamine should be selective, peripheral H1 receptor antagonist, should have a low affinity to the H1 receptors of the brain, be void of antikolinerg and antiserotonin effect, should stabilize the membrane of the mastocytes and/or have an impeding effect on eosinophil accommodation. The introduction of modern, second generation antihistamines was started by terfenadin in 1985, and was followed by astemizole, loratadine and cetirizine in 1988. The author gives a thorough survey of the pharmacokinetic characteristics of the second generation antihistamines and their clinical importance.

About this research paper

What this paper is about

In the 1980's a new group of antihistamines was developed, which has got, besides its increased efficiency, fewer by effects. Considering their pharmacokinetic characteristics and effects, the requirements the modern second generation antihistamine should meet, can be summarized as follows: the modern antihistamine should be selective, peripheral H1 receptor antagonist, should have a low affinity to the H1 receptors of the brain, be void of antikolinerg and antiserotonin effect, should stabilize the membrane of the mastocytes and/or have an impeding effect on eosinophil accommodation. The introduction of modern, second generation antihistamines was started by terfenadin in 1985, and was followed by astemizole, loratadine and cetirizine in 1988. The author gives a thorough survey of the pharmacokinetic characteristics of the second generation antihistamines and their clinical importance.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the 1980's a new group of antihistamines was developed, which has got, besides its increased efficiency, fewer by effects. Considering their pharmacokinetic characteristics and effects, the requirements the modern second generation antihistamine should meet, can be summarized as follows: the modern antihistamine should be selective, peripheral H1 receptor antagonist, should have a low affinity to the H1 receptors of the brain, be void of antikolinerg and antiserotonin effect, should stabilize the membrane of the mastocytes and/or have an impeding effect on eosinophil accommodation. The introduction of modern, second generation antihistamines was started by terfenadin in 1985, and was followed by astemizole, loratadine and cetirizine in 1988. The author gives a thorough survey of the pharmacokinetic characteristics of the second generation antihistamines and their clinical importance.

Key concepts: Loratadine, Antihistamine, Cetirizine, Astemizole, Levocetirizine, Histamine H1 receptor, Fexofenadine, Pharmacology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Second generation non-sedative antihistaminics]. — Research Paper | ScholarLens